Results 21 to 30 of about 48,247 (244)
The use of sofosbuvir for the treatment of recurrent hepatitis C after liver transplantation
Трансплантология (Москва), 2017 The article presents the experience of direct-acting antiviral (DAA) drug treatment for hepatitis C in the patients after liver transplantation. The end-stage liver disease caused by hepatitis C is the main indication for orthotopic liver transplantation
M. Sh. Khubutiya +5 more
doaj +1 more source
New drugs in the treatment of chronic hepatitis C [PDF]
Farmacia Hospitalaria, 2014 Objectives: To analyze the efficacy and safety of the new direct antiviralagents (DAA) that will become the new therapeutic arsenal for thetreatment of hepatitis C. Methods:We carried out a research in the electronic database with thefollowing criteria:
R. Jimenez Galan +4 more
doaj +1 more source
Livers, 2021 Chronic hepatitis C virus infection is still one of the major risk factors for the development of hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer.
Zuzana Macek Jilkova +3 more
doaj +1 more source
Retreatment Options Following HCV Direct-Acting Antiviral Failure [PDF]
Current Treatment Options in Infectious Diseases, 2017 Despite the excellent efficacy of direct acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug resistance, and lack of data regarding retreatment.
Autumn, Zuckerman +2 more
openaire +2 more sources
HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
Frontiers in Medicine, 2019 Hepatitis C virus (HCV) infection is a systemic disorder that frequently associates with extrahepatic manifestations, including nephropathies. Cryoglobulinemia is a typical extrahepatic manifestation of HCV infection that often involves kidneys with a ...
Andrea Angeletti +2 more
doaj +1 more source
Direct-acting antivirals and visceral leishmaniasis: a case report [PDF]
BMC Infectious Diseases, 2019 Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions of the immune system impair the capability to resolve the infection and allow reactivation from sites of latency
Colomba C. +7 more
openaire +4 more sources
F1000Research, 2016 Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs).
Sara Kishta +2 more
doaj +1 more source
Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis [PDF]
Терапевтический архив, 2018 Today, there is no complete clarity about the pathogenetic mechanisms of the hepatic decompensation in patients with HCV-cirrhosis during the course of direct-acting antiviral (DAAs) therapy. The current article describes several clinical observations of
S N Batskikh +3 more
doaj +1 more source
HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals [PDF]
Journal of Clinical and Translational Hepatology, 2016 Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade, resulting in better control of infection and clinical outcomes; however, drug-drug interactions remain a significant hazard. Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of ...
Rice, Donald P. +3 more
openaire +2 more sources
F1000Research, 2017 Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs).
Sara Sobhy Kishta +2 more
doaj +1 more source